Vaccination produces CD4 T cells with a novel CD154-CD40-dependent cytolytic mechanism

Journal of Immunology

Volumn 195, Issue 7, 2015, Pages 3190-3197

  Coler, Rhea N ^a,b,c   Hudson, Thomas ^a   Hughes, Sean ^a   Huang, Po Wei D ^a   Beebe, Elyse A ^a   Orr, Mark T ^a,b  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c PAI Life Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; DEATH RECEPTOR 5; FAS ANTIGEN; FAS LIGAND; GLA SE; GRANZYME A; GRANZYME B; PERFORIN; RECOMBINANT PROTEIN; TOLL LIKE RECEPTOR AGONIST; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EOMES; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; CYTOTOXIN; EOMES PROTEIN, MOUSE; GRANZYME; GRANZYME A, MOUSE; IMMUNOLOGICAL ADJUVANT; T BOX TRANSCRIPTION FACTOR; TNFSF10 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOLYSIS; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VACCINATION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGY; KNOCKOUT MOUSE; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD40; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; CYTOTOXINS; FAS LIGAND PROTEIN; GRANZYMES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; VACCINATION;

EID: 84942465670     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501118     Document Type: Article

References (50)

1. Lieberman, J. 2003. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat. Rev. Immunol. 3: 361-370.
2. Fleischer, B. 1984. Acquisition of specific cytotoxic activity by human T4+ T lymphocytes in culture. Nature 308: 365-367.
3. Marshall, N. B., and S. L. Swain. 2011. Cytotoxic CD4 T cells in antiviral immunity. J. Biomed. Biotechnol. 2011: 954602.
4. Soghoian, D. Z., and H. Streeck. 2010. Cytolytic CD4(+) T cells in viral immunity. Expert Rev. Vaccines 9: 1453-1463.
5. Jellison, E. R., S. K. Kim, and R. M. Welsh. 2005. Cutting edge: MHC class IIrestricted killing in vivo during viral infection. J. Immunol. 174: 614-618.
6. Brown, D. M., A. M. Dilzer, D. L. Meents, and S. L. Swain. 2006. CD4 T cellmediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J. Immunol. 177: 2888-2898.
7. Brien, J. D., J. L. Uhrlaub, and J. Nikolich-Zugich. 2008. West Nile virusspecific CD4 T cells exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection. J. Immunol. 181: 8568-8575.
8. Fang, M., N. A. Siciliano, A. R. Hersperger, F. Roscoe, A. Hu, X. Ma, A. R. Shamsedeen, L. C. Eisenlohr, and L. J. Sigal. 2012. Perforin-dependent CD4+ T-cell cytotoxicity contributes to control a murine poxvirus infection. Proc. Natl. Acad. Sci. USA 109: 9983-9988.
9. Appay, V., J. J. Zaunders, L. Papagno, J. Sutton, A. Jaramillo, A. Waters, P. Easterbrook, P. Grey, D. Smith, A. J. McMichael, et al. 2002. Characterization of CD4(+) CTLs ex vivo. J. Immunol. 168: 5954-5958.
10. Zheng, N., M. Fujiwara, T. Ueno, S. Oka, and M. Takiguchi. 2009. Strong ability of Nef-specific CD4+ cytotoxic T cells to suppress human immunodeficiency virus type 1 (HIV-1) replication in HIV-1-infected CD4+ T cells and macrophages. J. Virol. 83: 7668-7677.
11. Soghoian, D. Z., H. Jessen, M. Flanders, K. Sierra-Davidson, S. Cutler, T. Pertel, S. Ranasinghe, M. Lindqvist, I. Davis, K. Lane, et al. 2012. HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci. Transl. Med. 4: 123ra25.
12. Long, H. M., A. M. Leese, O. L. Chagoury, S. R. Connerty, J. Quarcoopome, L. L. Quinn, C. Shannon-Lowe, and A. B. Rickinson. 2011. Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition. J. Immunol. 187: 92-101.
13. Nikiforow, S., K. Bottomly, G. Miller, and C. Münz. 2003. Cytolytic CD4(+)-Tcell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. J. Virol. 77: 12088-12104.
14. van Leeuwen, E. M., E. B. Remmerswaal, M. H. Heemskerk, I. J. ten Berge, and R. A. van Lier. 2006. Strong selection of virus-specific cytotoxic CD4+ T-cell clones during primary human cytomegalovirus infection. Blood 108: 3121-3127.
15. Canaday, D. H., R. J. Wilkinson, Q. Li, C. V. Harding, R. F. Silver, and W. H. Boom. 2001. CD4(+) and CD8(+) T cells kill intracellular Mycobacterium tuberculosis by a perforin and Fas/Fas ligand-independent mechanism. J. Immunol. 167: 2734-2742.
16. Lewinsohn, D. M., T. T. Bement, J. Xu, D. H. Lynch, K. H. Grabstein, S. G. Reed, and M. R. Alderson. 1998. Human purified protein derivativespecific CD4+ T cells use both CD95-dependent and CD95-independent cytolytic mechanisms. J. Immunol. 160: 2374-2379.
17. Green, D. R., and T. A. Ferguson. 2001. The role of Fas ligand in immune privilege. Nat. Rev. Mol. Cell Biol. 2: 917-924.
18. Kayagaki, N., N. Yamaguchi, M. Nakayama, A. Kawasaki, H. Akiba, K. Okumura, and H. Yagita. 1999. Involvement of TNF-related apoptosisinducing ligand in human CD4+ T cell-mediated cytotoxicity. J. Immunol. 162: 2639-2647.
19. Woodworth, J. S., Y. Wu, and S. M. Behar. 2008. Mycobacterium tuberculosisspecific CD8+ T cells require perforin to kill target cells and provide protection in vivo. J. Immunol. 181: 8595-8603.
20. Qui, H. Z., A. T. Hagymasi, S. Bandyopadhyay, M. C. St Rose, R. Ramanarasimhaiah, A. Ménoret, R. S. Mittler, S. M. Gordon, S. L. Reiner, A. T. Vella, and A. J. Adler. 2011. CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation. J. Immunol. 187: 3555-3564.
21. Eshima, K., S. Chiba, H. Suzuki, K. Kokubo, H. Kobayashi, M. Iizuka, K. Iwabuchi, and N. Shinohara. 2012. Ectopic expression of a T-box transcription factor, eomesodermin, renders CD4(+) Th cells cytotoxic by activating both perforin- and FasL-pathways. Immunol. Lett. 144: 7-15.
22. Brown, D. M., C. Kamperschroer, A. M. Dilzer, D. M. Roberts, and S. L. Swain. 2009. IL-2 and antigen dose differentially regulate perforin- and FasL-mediated cytolytic activity in antigen specific CD4+ T cells. Cell. Immunol. 257: 69-79.
23. Orr, M. T., E. A. Beebe, T. E. Hudson, J. J. Moon, C. B. Fox, S. G. Reed, and R. N. Coler. 2014. A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93. PLoS One 9: e83884.
24. Orr, M. T., C. B. Fox, S. L. Baldwin, S. J. Sivananthan, E. Lucas, S. Lin, T. Phan, J. J. Moon, T. S. Vedvick, S. G. Reed, and R. N. Coler. 2013. Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. J. Control. Release 172: 190-200.
25. Coler, R. N., S. L. Baldwin, N. Shaverdian, S. Bertholet, S. J. Reed, V. S. Raman, X. Lu, J. DeVos, K. Hancock, J. M. Katz, et al. 2010. A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One 5: e13677.
26. Coler, R. N., S. Bertholet, M. Moutaftsi, J. A. Guderian, H. P. Windish, S. L. Baldwin, E. M. Laughlin, M. S. Duthie, C. B. Fox, D. Carter, et al. 2011. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 6: e16333.
27. Diehl, G. E., H. H. Yue, K. Hsieh, A. A. Kuang, M. Ho, L. A. Morici, L. L. Lenz, D. Cado, L. W. Riley, and A. Winoto. 2004. TRAIL-R as a negative regulator of innate immune cell responses. Immunity 21: 877-889.
28. Bertholet, S., G. C. Ireton, D. J. Ordway, H. P. Windish, S. O. Pine, M. Kahn, T. Phan, I. M. Orme, T. S. Vedvick, S. L. Baldwin, et al. 2010. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrugresistant Mycobacterium tuberculosis. Sci. Transl. Med. 2: 53ra74.
29. Baldwin, S. L., L. K. Ching, S. O. Pine, M. Moutaftsi, E. Lucas, A. Vallur, M. T. Orr, S. Bertholet, S. G. Reed, and R. N. Coler. 2013. Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells. J. Immunol. 191: 2514-2525.
30. Zhu, Y., S. Ju, E. Chen, S. Dai, C. Li, P. Morel, L. Liu, X. Zhang, and B. Lu. 2010. T-bet and eomesodermin are required for T cell-mediated antitumor immune responses. J. Immunol. 185: 3174-3183.
31. Dorothée, G., I. Vergnon, J. Menez, H. Echchakir, D. Grunenwald, M. Kubin S. Chouaib, and F. Mami-Chouaib. 2002. Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity. J. Immunol. 169: 809-817.
32. Tite, J. P. 1990. Evidence of a role for TNF-alpha in cytolysis by CD4+, class II MHC-restricted cytotoxic T cells. Immunology 71: 208-212.
33. Brown, D. M. 2010. Cytolytic CD4 cells: direct mediators in infectious disease and malignancy. Cell. Immunol. 262: 89-95.
34. Hildemann, S. K., J. Eberlein, B. Davenport, T. T. Nguyen, F. Victorino, and D. Homann. 2013. High efficiency of antiviral CD4(+) killer T cells. PLoS One 8: e60420.
35. Bijker, E. M., A. C. Teirlinck, R. Schats, G. J. van Gemert, M. van de Vegte-Bolmer, L. van Lieshout, J. IntHout, C. C. Hermsen, A. Scholzen, L. G. Visser, and R. W. Sauerwein. 2014. Cytotoxic markers associate with protection against malaria in human volunteers immunized with Plasmodium falciparum sporozoites. J. Infect. Dis. 210: 1605-1615.
36. Stuller, K. A., and E. Flaño. 2009. CD4 T cells mediate killing during persistent gammaherpesvirus 68 infection. J. Virol. 83: 4700-4703.
37. Elgueta, R., M. J. Benson, V. C. de Vries, A. Wasiuk, Y. Guo, and R. J. Noelle. 2009. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 229: 152-172.
38. Hua, L., S. Yao, D. Pham, L. Jiang, J. Wright, D. Sawant, A. L. Dent, T. J. Braciale, M. H. Kaplan, and J. Sun. 2013. Cytokine-dependent induction of CD4+ T cells with cytotoxic potential during influenza virus infection. J. Virol. 87: 11884-11893.
39. Frentsch, M., O. Arbach, D. Kirchhoff, B. Moewes, M. Worm, M. Rothe, A. Scheffold, and A. Thiel. 2005. Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat. Med. 11: 1118-1124.
40. Bhushan, A., and L. R. Covey. 2001. CD40:CD40L interactions in X-linked and non-X-linked hyper-IgM syndromes. Immunol. Res. 24: 311-324.
41. Hennino, A., M. Bérard, P. H. Krammer, and T. Defrance. 2001. FLICEinhibitory protein is a key regulator of germinal center B cell apoptosis. J. Exp. Med. 193: 447-458.
42. Tuscano, J. M., K. M. Druey, A. Riva, J. Pena, C. B. Thompson, and J. H. Kehrl. 1996. Bcl-x rather than Bcl-2 mediates CD40-dependent centrocyte survival in the germinal center. Blood 88: 1359-1364.
43. Wong, B. R., R. Josien, S. Y. Lee, B. Sauter, H. L. Li, R. M. Steinman, and Y. Choi. 1997. TRANCE (tumor necrosis factor [TNF]-related activationinduced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186: 2075-2080.
44. Eliopoulos, A. G., C. Davies, P. G. Knox, N. J. Gallagher, S. C. Afford, D. H. Adams, and L. S. Young. 2000. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol. Cell. Biol. 20: 5503-5515.
45. Lee, J. K., N. Seki, T. J. Sayers, J. Subleski, E. M. Gruys, W. J. Murphy, and R. H.Wiltrout. 2005. Constitutive expression of functional CD40 on mouse renal cancer cells: induction of Fas and Fas-mediated killing by CD40L. Cell. Immunol. 235: 145-152.
46. Alexandroff, A. B., A. M. Jackson, T. Paterson, J. L. Haley, J. A. Ross, D. L. Longo, W. J. Murphy, K. James, and D. D. Taub. 2000. Role for CD40-CD40 ligand interactions in the immune response to solid tumours. Mol. Immunol. 37: 515-526.
47. Tong, A. W., M. H. Papayoti, G. Netto, D. T. Armstrong, G. Ordonez, J. M. Lawson, and M. J. Stone. 2001. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin. Cancer Res. 7: 691-703.
48. von Leoprechting, A., P. van der Bruggen, H. L. Pahl, A. Aruffo, and J. C. Simon. 1999. Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res. 59: 1287-1294.
49. Lewis, T. S., R. S. McCormick, I. J. Stone, K. Emmerton, B. Mbow, J. Miyamoto, J. G. Drachman, I. S. Grewal, and C. L. Law. 2011. Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells. Leukemia 25: 1007-1016.
50. Lewis, T. S., R. S. McCormick, K. Emmerton, J. T. Lau, S. F. Yu, J. A. McEarchern, I. S. Grewal, and C. L. Law. 2011. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma. Clin. Cancer Res. 17: 4672-4681.